Skip to content

HSBC Lifts GSK Stock Rating as Management Change Signals Pipeline Turning Point

HSBC upgraded GSK (LON: GSK) (NYSE: GSK) to Hold from Reduce on Monday, raising its price target to 1,860 pence from 1,500 pence, citing signs that new management is taking a more proactive approach to rebuilding the pharmaceutical giant’s pipeline.

GSK.LSE

The bank told investors in a note that the key concern hanging over GSK has long been a significant patent cliff and insufficient pipeline strength to replace the earnings power set to be lost when key drugs lose exclusivity.

However, HSBC said the change in management and a recent willingness to reinvest in the pipeline to drive future growth suggest the company “might be turning a corner.”

The upgrade follows a similar move by Kepler Cheuvreux in May, when analyst Nicolas Pauillac lifted GSK from Hold to Buy with a price target of 2,516 pence, arguing the stock’s discount to peers was difficult to justify given improving operational delivery.

Pauillac noted GSK trades at approximately 10 times 2027 earnings estimates, a clear discount to the peer average of around 14.8 times, while around half of sell-side ratings remain at Hold. He said that scepticism “contrasts with the company’s improved operational delivery, repeated upgrades to management’s long-term outlook, and a risk-adjusted £40 billion revenue ambition for 2031.”

GSK shares slipped 1.6% on Monday but remain up 8.5% year-to-date. According to TradingView data, five of 20 analysts rate the stock a Buy, 12 a Hold, and 3 a Sell.

Searching for the Perfect Broker?

Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!

YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY

Sam Boughedda
Sam Boughedda
Team Member

Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples. 

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.